Merck's Phase 3 KEYFORM-007 study on the combination of favezelimab and pembrolizumab in MSS mCRC patients did not improve overall survival compared to standard treatments, though safety remained consistent.

Merck (MRK) stock is in focus as a Phase 3 trial for its cancer drug Keytruda in colorectal cancer patients did not meet primary endpoint. Read more here.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for its combo regimen of a PD-1 blocker and an anti-LAG-3 antibody.

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously treated patients with a type of colorectal cancer. Th

Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC).